>
Switch to:

Biomarin Pharmaceutical Inventory-to-Revenue

: 1.79 (As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biomarin Pharmaceutical's Total Inventories for the quarter that ended in Sep. 2021 was $730 Mil. Biomarin Pharmaceutical's Revenue for the three months ended in Sep. 2021 was $409 Mil. Biomarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Sep. 2021 was 1.79.

Biomarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Sep. 2021 increased from Jun. 2021 (1.42) to Jun. 2021 (1.79)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biomarin Pharmaceutical's Days Inventory for the three months ended in Sep. 2021 was 643.54.

Total Inventories can be measured by Days Sales of Inventory (DSI). Biomarin Pharmaceutical's days sales of inventory (DSI) for the three months ended in Sep. 2021 was 163.01.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biomarin Pharmaceutical's Inventory Turnover for the quarter that ended in Sep. 2021 was 0.14.


Biomarin Pharmaceutical Inventory-to-Revenue Historical Data

The historical data trend for Biomarin Pharmaceutical's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Inventory-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.32 0.34 0.36 0.37

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 1.55 1.45 1.42 1.79

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Inventory-to-Revenue falls into.



Biomarin Pharmaceutical Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biomarin Pharmaceutical's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Inventory-to-Revenue (A: Dec. 2020 )
=Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2019 ) + Total Inventories (A: Dec. 2020 )) / count ) / Revenue (A: Dec. 2020 )
=( (680.275 + 698.548) / 2 ) / 1860.461
=689.4115 / 1860.461
=0.37

Biomarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Sep. 2021 is calculated as

Inventory-to-Revenue (Q: Sep. 2021 )
=Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2021 ) + Total Inventories (Q: Sep. 2021 )) / count ) / Revenue (Q: Sep. 2021 )
=( (710.975 + 749.406) / 2 ) / 408.742
=730.1905 / 408.742
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (NAS:BMRN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biomarin Pharmaceutical's Days Inventory for the three months ended in Sep. 2021 is calculated as:

Days Inventory=Total Inventories (Q: Sep. 2021 )/Cost of Goods Sold (Q: Sep. 2021 )*Days in Period
=730.1905/103.537*365 / 4
=643.54

2. Total Inventories can be measured by Days Sales of Inventory (DSI).

Biomarin Pharmaceutical's Days Sales of Inventory for the three months ended in Sep. 2021 is

Days Sales of Inventory (DSI)=Total Inventories (Q: Sep. 2021 )/Revenue (Q: Sep. 2021 )*Days in Period
=730.1905/408.742*365 / 4
=163.01

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biomarin Pharmaceutical's Inventory Turnover for the quarter that ended in Sep. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2021 ) / Total Inventories (Q: Sep. 2021 )
=103.537 / 730.1905
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)